Zydus to Buy Assertio for $166.4 Million to Expand U.S. Oncology Platform

**Zydus Lifesciences will acquire U.S. oncology supportive‑care company Assertio for $166.4 million, gaining an approved drug and a commercial platform to strengthen its U.S. specialty business.

Zydus Lifesciences, based in India, announced that its wholly owned subsidiary Zara Merger Sub Inc. will launch a tender offer for all outstanding shares of Assertio Holdings, Inc.

The offer prices each share at $23.50 in cash, valuing the deal at $166.4 million on a fully‑diluted basis. Closing is expected in fiscal year 2026‑27, subject to customary conditions including a majority tender.

Under the merger agreement, Zydus will first conduct a tender offer; shares not tendered will be acquired in a second‑step merger at the same price.

Zydus said the acquisition gives it an established U.S. specialty oncology commercial platform backed by Assertio’s oncology supportive‑care presence.

Assertio’s portfolio includes ROLVEDON® (eflapegrastimxnst), a long‑acting GCSF biologic approved by the FDA to prevent febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy.

Sharvil P. Patel, Managing Director of Zydus Lifesciences, called the deal a strategic step to boost the company’s U.S. specialty oncology footprint and align it with its long‑term strategy.

By adding Assertio’s approved asset and commercial team, Zydus can accelerate its presence in the U.S. oncology supportive‑care market, a segment that has shown steady growth.

The transaction also diversifies Zydus’ revenue base beyond its traditional generics and biosimilars businesses, reinforcing its goal of building durable specialty franchises worldwide.

Analysts note that the combined entity could cross‑sell Assertio’s supportive‑care products with Zydus’ existing oncology pipeline, though specific synergies have not been quantified.

Investors will watch for the tender offer to start within five business days of the agreement and for any regulatory updates that could affect the FY2026‑27 closing date.